Caroline J. Springer

Caroline J. Springer

Auto-generated profile, based on publicly available information

Caroline J. Springer

The Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Cell
Verified
Journal Article
Closed access
PWPaul T.C Wan
Paul T.C Wan
MGMathew J Garnett
Mathew J Garnett
SRS Roe
S Roe
SLSharlene Lee
Sharlene Lee
DNDan Niculescu-Duvaz
Dan Niculescu-Duvaz
RMRichard Marais
Richard Marais

1 January 2010 in Cell
Verified
Journal Article
Open access
SHSonja J. Heidorn
Sonja J. Heidorn
CMCarla Milagre
Carla Milagre
SWSteven Whittaker
Steven Whittaker
ANArnaud Nourry
Arnaud Nourry
INIon Niculescu-Duvas
Ion Niculescu-Duvas
RMRichard Marais
Richard Marais
We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling. This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS. Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice. Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression. They highlight the importance of understanding pathway signaling in clinical practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.

19 January 2012 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
FSFei Su
Fei Su
AVAmaya Viros
Amaya Viros
CMCarla Milagre
Carla Milagre
KTKerstin Trunzer
Kerstin Trunzer
GBGideon Bollag
Gideon Bollag
RMRichard Marais
Richard Marais
Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors. We performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib. An analysis of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed. Among 21 tumor samples, 13 had RAS mutations (12 in HRAS). In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS). Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L. Increased proliferation of HRAS Q61L–mutant cell lines exposed to vemurafenib was associated with mitogen-activated protein kinase (MAPK)–pathway signaling and activation of ERK-mediated transcription. In a mouse model of HRAS Q61L–mediated skin carcinogenesis, the vemurafenib analogue PLX4720 was not an initiator or a promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor. Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib. The molecular mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions. (Funded by Hoffmann–La Roche and others; ClinicalTrials.gov numbers, NCT00405587, NCT00949702, NCT01001299, and NCT01006980.)

21 June 2004 in Oncogene
Verified
Journal Article
Closed access
MKMaria Karasarides
Maria Karasarides
ACAntonio Chiloeches
Antonio Chiloeches
RHRobert Hayward
Robert Hayward
DNDan Niculescu-Duvaz
Dan Niculescu-Duvaz
ISIan Scanlon
Ian Scanlon
RMRichard Marais
Richard Marais

1 February 2013 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MGMaria R. Girotti
Maria R. Girotti
MPMalin Pedersen
Malin Pedersen
BSBerta Sanchez-Laorden
Berta Sanchez-Laorden
AVAmaya Viros
Amaya Viros
STSamra Turajlic
Samra Turajlic
RMRichard Marais
Richard Marais
We generated cell lines resistant to BRAF inhibitors and show that the EGF receptor (EGFR)–SRC family kinase (SFK)–STAT3 signaling pathway was upregulated in these cells. In addition to driving proliferation of resistant cells, this pathway also stimulated invasion and metastasis. EGFR inhibitors cooperated with BRAF inhibitors to block the growth of the resistant cells in vitro and in vivo, and monotherapy with the broad specificity tyrosine kinase inhibitor dasatinib blocked growth and metastasis in vivo. We analyzed tumors from patients with intrinsic or acquired resistance to vemurafenib and observed increased EGFR and SFK activity. Furthermore, dasatinib blocked the growth and metastasis of one of the resistant tumors in immunocompromised mice. Our data show that BRAF inhibitor-mediated activation of EGFR–SFK–STAT3 signaling can mediate resistance in patients with BRAF-mutant melanoma. We describe 2 treatments that seem to overcome this resistance and could deliver therapeutic efficacy in patients with drug-resistant BRAF-mutant melanoma. Significance: Therapies that target the driver oncogenes in cancer can achieve remarkable responses if patients are stratified for treatment. However, as with conventional therapies, patients often develop acquired resistance to targeted therapies, and a proportion of patients are intrinsically resistant and fail to respond despite the presence of an appropriate driver oncogene mutation. We found that the EGFR/SFK pathway mediated resistance to vemurafenib in BRAF-mutant melanoma and that BRAF and EGFR or SFK inhibition blocked proliferation and invasion of these resistant tumors, providing potentially effective therapeutic options for these patients. Cancer Discov; 3(2); 158–67. ©2012 AACR. This article is highlighted in the In This Issue feature, p. 125

1 September 2021 in Cancer Cell
Verified
Journal Article
Open access
CHColin Hutton
Colin Hutton
FHFelix Heider
Felix Heider
ABAdrian Blanco-Gomez
Adrian Blanco-Gomez
ABAntonia Banyard
Antonia Banyard
AKAlexander Kononov
Alexander Kononov
CJClaus Jørgensen
Claus Jørgensen
Fibroblasts display extensive transcriptional heterogeneity, yet functional annotation and characterization of their heterocellular relationships remains incomplete. Using mass cytometry, we chart the stromal composition of 18 murine tissues and 5 spontaneous tumor models, with an emphasis on mesenchymal phenotypes. This analysis reveals extensive stromal heterogeneity across tissues and tumors, and identifies coordinated relationships between mesenchymal and immune cell subsets in pancreatic ductal adenocarcinoma. Expression of CD105 demarks two stable and functionally distinct pancreatic fibroblast lineages, which are also identified in murine and human healthy tissues and tumors. Whereas CD105-positive pancreatic fibroblasts are permissive for tumor growth in vivo, CD105-negative fibroblasts are highly tumor suppressive. This restrictive effect is entirely dependent on functional adaptive immunity. Collectively, these results reveal two functionally distinct pancreatic fibroblast lineages and highlight the importance of mesenchymal and immune cell interactions in restricting tumor growth.